{"id":104308,"date":"2026-07-16T18:33:34","date_gmt":"2026-07-16T18:33:34","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/104308\/"},"modified":"2026-07-16T18:33:34","modified_gmt":"2026-07-16T18:33:34","slug":"aaic26-roche-charts-expanded-course-for-alzheimers-therapy-touts-long-term-anti-amyloid-impact","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/104308\/","title":{"rendered":"AAIC26: Roche charts expanded course for Alzheimer\u2019s therapy, touts long-term anti-amyloid impact"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">Roche is eyeing a wider patient population for its anti-amyloid Alzheimer&#8217;s hopeful, trontinemab, as the space increasingly examines the potential of early treatment in boosting patient outcomes.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The Swiss pharma giant plans to do this through the PrevenTRON study it announced at the 2026 Alzheimer&#8217;s Association International Conference (AAIC) in London, which Roche&#8217;s trontinemab global development leader, Janice Smith, said is set to initiate within a few months.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">In this study, Roche will look how effective trontinemab may be in both asymptomatic and transitional patients displaying Alzheimer&#8217;s-related biomarkers.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">To recruit for this study, Roche has harnessed its TRAVELLER registry, which is designed to reduce the screening burden for patients, while enhancing the company&#8217;s capacity to rapidly identify individuals that are eligible for treatment. By incorporating a consent form alongside a blood-based biomarker and cognitive test, Roche aims to allow patients to determine their eligibility without fully committing to a clinical trial.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Roche makes these moves as both Eli Lilly and Biogen &amp; Eisai also explore the potential of their respective, approved anti-amyloid therapies Kisunla (donanemab) and Leqembi (lecanemab) in the preclinical population, as researchers theorise that targeting amyloid pathology earlier on could improve outcomes in Alzheimer&#8217;s disease.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Alongside the early treatment approach, researchers in the drug development space are also increasingly looking at preventative approaches to Alzheimer&#8217;s \u2013 with an example being cardiology biotech, NewAmsterdam. At AAIC 2026, the company presented Phase III data from the <a data-ylk=\"slk:BROADWAY study;elm:context_link;itc:0;sec:content-canvas;\" data-yga=\"{&quot;yLinkElement&quot;:&quot;link&quot;,&quot;yLinkElementType&quot;:&quot;article_link&quot;}\" href=\"https:\/\/www.clinicaltrialsarena.com\/news\/newamsterdam-alzheimers-disease-obiceptrapib\/\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">BROADWAY study<\/a> (NCT05142722), which revealed that its LDL cholesterol-lowering drug, obicetrapib, significantly reduced the presence of key Alzheimer&#8217;s biomarker p-tau217 in patients with at least one copy of the APOE4 gene \u2013 highlighting its potential role in staving off disease progression in Alzheimer&#8217;s.<\/p>\n<p>OLE data cements trontinemab&#8217;s Phase III development<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Alongside the PrevenTRON announcement at AAIC 2026, Roche debuted new trontinemab efficacy and biomarker data from a portion of the open-label extension (OLE) segment of the Phase Ib\/IIa Brainshuttle AD study (NCT04639050) \u2013 shining a spotlight on its potential to compete with approved anti-amyloid therapies like Kisunla and Leqembi.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">At the conference, the company revealed that 92% of patients given the higher, 3.6mg\/kg dose of trontinemab fell below the amyloid positivity threshold at 28 weeks \u2013 a feat that 65% of patients in the 1.8mg\/kg group achieved.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Trontinemab was also found to provide continued amyloid reduction from baseline throughout the one-year OLE period, as measured by an amyloid PET scan.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">In the presentation, Roche also touted the safety and tolerability profile of trontinemab, noting that infusion-related reactions (IRRs) \u2013 a common side effect of anti-amyloid therapies \u2013 occurred in seven (8.6%) of the 81 patients assigned to the trontinemab 12-weekly maintenance schedule. Anaemia cases were also low in this population, with three patients (3.7%) enduring this side effect up to the treatment cutoff.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Despite this, eight patients did experience brain microhaemorrhaging during the maintenance period, and there was a case of brain swelling linked to treatment. According to Jefferies analysts, this &#8220;poses a question on just how clean the safety profile [of trontinemab] actually is.&#8221; A male patient in the trontinemab treatment group also died two months after his last dose in the OLE portion of the trial, though Roche deemed this fatality, caused by a ruptured artery, unrelated to the study drug.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">According to the Swiss pharma giant, these results support the induction and maintenance dosing regimens used in the Phase III TRONTIER 1 and 2 studies, which are currently ongoing.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">If approved, trontinemab would become the third anti-amyloid therapy to reach the market \u2013 joining Eli Lilly&#8217;s Kisunla and Biogen &amp; Eisai&#8217;s Leqembi on the market as their uptake in <a data-ylk=\"slk:Alzheimer&#039;s treatment;elm:context_link;itc:0;sec:content-canvas;\" data-yga=\"{&quot;yLinkElement&quot;:&quot;link&quot;,&quot;yLinkElementType&quot;:&quot;article_link&quot;}\" href=\"https:\/\/www.globaldata.com\/store\/industry\/alzheimers-disease-market\/\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">Alzheimer&#8217;s treatment<\/a> grows. As per GlobalData&#8217;s Pharmaceutical Intelligence Center, Leqembi and Kisunla will join become blockbuster therapies in 2027 and 2028, respectively. However, they will need to navigate ongoing reimbursement challenges.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">GlobalData is the parent company of Clinical Trials Arena.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">&#8220;AAIC26: Roche charts expanded course for Alzheimer&#8217;s therapy, touts long-term anti-amyloid impact&#8221; was originally created and published by <a data-ylk=\"slk:Clinical Trials Arena;elm:context_link;itc:0;sec:content-canvas;\" data-yga=\"{&quot;yLinkElement&quot;:&quot;link&quot;,&quot;yLinkElementType&quot;:&quot;article_link&quot;}\" href=\"https:\/\/www.clinicaltrialsarena.com\/news\/roche-alzheimers-trontinemab-aaic-26\/\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">Clinical Trials Arena<\/a>, a GlobalData owned brand.<\/p>\n","protected":false},"excerpt":{"rendered":"Roche is eyeing a wider patient population for its anti-amyloid Alzheimer&#8217;s hopeful, trontinemab, as the space increasingly examines&hellip;\n","protected":false},"author":2,"featured_media":104309,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[48953,48958,15909,3752,134],"class_list":["post-104308","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-aaic","tag-alzheimers-association","tag-alzheimers-disease","tag-patients","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116931094516602908","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/104308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=104308"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/104308\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/104309"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=104308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=104308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=104308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}